Skip to main navigation Skip to search Skip to main content

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

  • Matteo Santoni
  • , Zin W. Myint
  • , Thomas Büttner
  • , Hideki Takeshita
  • , Yohei Okada
  • , Elaine T. Lam
  • , Danielle Gilbert
  • , Zsófia Küronya
  • , Deniz Tural
  • , Renate Pichler
  • , Enrique Grande
  • , Simon J. Crabb
  • , Robert Kemp
  • , Francesco Massari
  • , Sarah Scagliarini
  • , Roberto Iacovelli
  • , Nuno Vau
  • , Umberto Basso
  • , Marco Maruzzo
  • , Javier Molina-Cerrillo
    • Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popovic, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindrich Kopecky, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino M. Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science